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Bacterial antibiotic resistance has increased in recent decades, raising concerns in
hospital and community settings. Novel, innovative strategies are needed to eradicate
bacteria, particularly within biofilms, and diminish the likelihood of recurrence. In this
study, we investigated whether glutathione (GSH) can act as a biofilm disruptor, and
enhance antibiotic effectiveness against various bacterial pathogens. Biological levels
(10 mM) of GSH did not have a significant effect in inhibiting growth or disrupting the
biofilm in four out of six species tested. However, exposure to 30 mM GSH showed
>50% decrease in growth for all bacterial species, with almost 100% inhibition of
Streptococcus pyogenes and an average of 94–52% inhibition for Escherichia coli,
Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive S. aureus
(MSSA) and multi-drug resistant Acinetobacter baumannii (MRAB) isolates, respectively.
Klebsiella pneumoniae and Enterobacter sp. isolates were however, highly resistant to
30 mM GSH. With respect to biofilm viability, all species exhibited a >50% decrease
in viability with 30 mM GSH, with confocal imaging showing considerable change in
the biofilm architecture of MRAB isolates. The mechanism of GSH-mediated biofilm
disruption is possibly due to a concentration-dependent increase in GSH acidity that
triggers cleaving of the matrix components. Enzymatic treatment of MRAB revealed
that eDNA and polysaccharides are essential for biofilm stability and eDNA removal
enhanced amikacin efficiency. Combination of GSH, amikacin and DNase-I showed the
greatest reduction in MRAB biofilm viability. Additionally, GSH alone and in combination
with amikacin fostered human fibroblast cell (HFF-1) growth and confluence while
inhibiting MRAB adhesion and colonization.
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INTRODUCTION
The spread of antibiotic resistance in the hospital environment and in community settings
particularly where biofilms are involved, has spurred development of new strategies to design
innovative therapeutics to curtail the spread of resistance. In 2016, a review commissioned by the
UK government concluded that approximately 700,000 people die each year around the globe from
antibiotic-resistant infections (O’Neill, 2016). In Australia, the burden of Healthcare-associated
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infections are estimated around 165,000 annually comprising
bacterial associated urinary tract infections, blood stream
infection, pneumonia, surgical site infections, respiratory
Infections etc. (Mitchell et al., 2017). In addition, antibiotic
resistance has a serious global economic impact. It has been
projected that antibiotic resistance will cost US$100 trillion
worldwide by 2050, with an estimated yearly death toll reaching
10 million during that period (O’Neill, 2015). Bacterial resistance
is critically exacerbated through the extensive and unwarranted
use of antibiotics in sectors including aged care, human and
hospital usage, agriculture and food animal production. Current
statistics suggest that India, China, United States, Russia,
Brazil, and South Africa are the world leaders in per capita
consumption of antibiotics (Van Boeckel et al., 2014). A report
by Antimicrobial Use and Resistance in Australia (AURA) 2017
suggests extensive misuse of antibiotics is occurring in Australian
hospitals e.g., in 2015, 40.5% of hospital in-patients were being
prescribed an antimicrobial, with 21.9% of cases considered
inappropriate and 23.3% of antimicrobial prescriptions were
non-compliant with guidelines (AURA, 2017).
Bacteria in biofilm growth phase are principally responsible
for an array of infections within hospital, general health care and
community settings (Jamal et al., 2018). Bacterial self-produced
extracellular molecules such as extracellular DNA (eDNA),
polysaccharides, proteins and metabolites aids them to adhere
and colonize on surfaces and forms structurally stable biofilm
matrix (Flemming and Wingender, 2010; Das et al., 2011, 2013).
Bacteria embedded in its matrix endure substantial physical
stress (shear) and significantly, higher chemical stress than
planktonic bacteria, including stress from antibiotics, antiseptics
and detergents (Lewis, 2001; Mahzounieh et al., 2014; Karimi
et al., 2015; Peterson et al., 2015; Wilton et al., 2016; Clayton
and Thien-Fah, 2017). Bacteria in its biofilm state also resist
host immune response and triggers infection (Domenech et al.,
2013; Watters et al., 2016). Due to the slow diffusion of the
antibiotics through biofilm matrix, the presence of biofilms
represents a big eradication challenge compared to planktonic
bacteria (Lewis, 2001; Wilton et al., 2016; Clayton and Thien-
Fah, 2017). Biofilm-associated infections in a host lead to
changes in various vital biological systems such the host immune
response. They also lead to depletion of antioxidants such as
glutathione (GSH), the master antioxidant in all mammalian
cells. The depletion of GSH has been directly linked to an
increase in pathogenicity of infection (Ristoff et al., 2001;
Ghezzi, 2011). GSH depletion during bacterial infection induces
oxidative stress in host cells and consequently inhibits cell
growth, thus triggering cell death (Ristoff et al., 2001; Ghezzi,
2011). GSH is a thiol (-SH) based tripeptide antioxidant, and
in protecting mammalian cells against oxidative stress, it aids in
cell cycle regulation and growth as well as maintenance of redox
homeostasis (Forman et al., 2009). In our previous study, we
elucidated GSH’s significant role in neutralizing the cytotoxicity
of the Pseudomonas aeruginosa virulence factor pyocyanin, and
facilitating the growth of human lung epithelial cells (Das et al.,
2017). In P. aeruginosa biofilms, GSH directly interacts with
pyocyanin and modulates its structure to inhibit pyocyanin
intercalation with DNA and biofilm integration and in this way
disrupts the biofilm matrix and enhances antibiotic efficiency
(Das et al., 2015; Klare et al., 2016).
Amongst the ESKAPE (Enterococcus faecium, Staphylococcus
aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa, and Enterobacter species) pathogens,
prominent biofilm forming bacteria include S. aureus and
A. baumannii. A. baumannii, a Gram-negative emerging
pathogen, has garnered attention in recent years due to its
inherent multidrug resistant (MDR) profile and pathogenicity,
responsible for causing nosocomial infections in hospitalized
patients, skin and soft tissue infections especially predominate
in combat-associated wounds, morbidity, and mortality in
weakened and critically ill patients (Joly-Guillou, 2005; Perez
et al., 2007; Fishbain and Peleg, 2010). The World Health
Organization (WHO) has classified A. baumannii as of critical
importance alongside P. aeruginosa and the Enterobacter sp.
whereas; S. aureus are classified as of high importance1.
In this study, we aimed to identify whether GSH plays a role
in biofilm disruption in non-pyocyanin-expressing pathogenic
species. These experiments included testing the effect of a
combination treatment (CT) comprising GSH and an antibiotic
of choice, on clinical strains. Strains included four bacterial
species of the ESKAPE group of pathogens: A. baumannii,
methicillin resistant S. aureus (MRSA) and methicillin sensitive
S. aureus (MSSA), Enterobacter sp. (E. cloacae and E. aerogenes)
and K. pneumoniae as well as the non-ESKAPE pathogens
Streptococcus pyogenes and Escherichia coli, all clinical isolates
sourced from Sydney hospital culture collections. Most of the
bacterial isolates used in this study were strongly susceptible to
ciprofloxacin, whereas the multi drug resistant A. baumannii
(MRAB) isolates were sensitive only to amikacin. The study was
also expanded in the case of A. baumannii to investigate the
effect of enzymes on the efficiency of GSH plus amikacin (a triple
combination therapy), in disrupting MRAB biofilms.
MATERIALS AND METHODS
Bacterial Strains
Species used in this study were S. aureus (MRSA and
MSSA), S. pyogenes, A. baumannii (MRAB), Enterobacter sp.,
K. pneumoniae and E. coli. Strains were obtained from Royal
Prince Alfred Hospital, Concord Hospital and the High Risk
Foot Service clinic at Liverpool Hospital, all located in Sydney,
Australia. The Tissue Act (NSW, 1983)2 did not require the study
to be reviewed or approved because: all species/strains were de-
identified by the hospitals concerned prior to being gifted to us,
all species/strains were from their historical culture collections,
and they were not collected from patients as part of this study.
Table 1 lists the species/strains, their source (hospital details)
and antibiotic MIC’s. The ciprofloxacin MIC for as measured
for each species was: [S. aureus MRSA and MSSA (=10 µg/ml);
S. pyogenes (4 µg/ml); Enterobacter sp. (=0.5 µg/ml); E. coli
1https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-
bacteria-for-which-new-antibiotics-are-urgently-needed
2https://www.legislation.nsw.gov.au/inforce/dae79cae-8043-47df-9c37-
fe8d1d7e38b3/1983-164.pdf
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TABLE 1 | Source and antibiotic profile of bacterial species/strains obtained from hospital culture collections.
Source Antibiotic profile∗
Bacterial species Amk Aug Amx Cip Gen Tob
Staphylococcus aureus (MRSA)
MRSA-1 (Left leg wound) Microbiology Department, RPAH, Sydney, NSW, Australia NT R R S S NT
MRSA-2 (Chin vesicle) Microbiology Department, RPAH, Sydney, NSW, Australia NT R R S S NT
MRSA-3 (DFU) The High-Risk Foot Service clinic, Liverpool hospital, Sydney, NSW, Australia R R R R R R
Staphylococcus aureus (MSSA)
MSSA-1 (Left elbow) Microbiology Department, RPAH, Sydney, NSW, Australia NT S R S S NT
MSSA-2 (Right toe) Microbiology Department, RPAH, Sydney, NSW, Australia NT S R S S NT
MSSA-3 (DFU) The High-Risk Foot Service clinic, Liverpool hospital, Sydney, NSW, Australia R S S R R R
Streptococcus pyogenes
SP-1 (left leg boil) Microbiology Department, RPAH, Sydney, NSW, Australia NT S S S NT NT
SP-2 (head wound) Microbiology Department, RPAH, Sydney, NSW, Australia NT S S S NT NT
SP-3 (skin wound) Microbiology Department, RPAH, Sydney, NSW, Australia NT S S S NT NT
Acinetobacter baumannii
MRAB-1 (Urine) Microbiology Department, Concord Hospital, NSW, Australia S R R R R R
MRAB-2 (Catheter) Microbiology Department, Concord Hospital, NSW, Australia S R R R R R
MRAB-3 (Skin) Microbiology Department, Concord Hospital, NSW, Australia S R R R R R
MRAB-4 (Catheter) Microbiology Department, Concord Hospital, NSW, Australia S R R R R R
Enterobacter Species
ENTC-1 (Ear) Microbiology Department, RPAH, Sydney, NSW, Australia S R R S S S
ENTC-2 (Wound) Microbiology Department, RPAH, Sydney, NSW, Australia S R R S R R
ENTA-1 (Sternum) Microbiology Department, RPAH, Sydney, NSW, Australia S R R S S S
Escherichia coli
EC-1 (Drain fluid) Microbiology Department, RPAH, Sydney, NSW, Australia S S R S S S
EC-2 (Wound) Microbiology Department, RPAH, Sydney, NSW, Australia S R R S S S
EC-3 (Exit site) Microbiology Department, RPAH, Sydney, NSW, Australia S S S S S S
Klebsiella pneumoniae
KP-1 (Catheter urine) Microbiology Department, RPAH, Sydney, NSW, Australia S R R S S S
KP-2 (Left hip wound) Microbiology Department, RPAH, Sydney, NSW, Australia S I R I R S
KP-3 (Neck pus) Microbiology Department, RPAH, Sydney, NSW, Australia S S R S S S
RPAH, Royal Prince Alfred Hospital; DFU, diabetic foot ulcer; Antibiotics: Amk, amikacin; Aug, augmentin; Amx, amoxicillin; Cip, ciprofloxacin; Gen, gentamicin; Tob,
tobramycin; NT, not tested; R, resistance; S, sensitive, and I, intermediate. Ciprofloxacin MIC: S. aureus MRSA and MSSA (=10 µg/ml); S. pyogenes (4 µg/ml);
Enterobacter sp. (=0.5 µg/ml); E. coli (=0.5 µg/ml); K. pneumoniae (=10 µg/ml). Amikacin MIC for A. baumannii (4 µg/ml).
(=0.5 µg/ml); K. pneumoniae (=10 µg/ml)], and the amikacin
MIC was (4 µg/ml) for MRAB.
General Chemicals Used for This Study
Glutathione, Glutathione disulfide (GSSG), antibiotics (cipro-
floxacin, amikacin, Augmentin, gentamicin and tobramycin),
resazurin dye, crystal violet solution, Phosphate buffered saline
(1× PBS) and Hydrogen peroxide (H2O2) were all obtained from
Sigma-Aldrich (Sydney, Australia). Tryptone Soy Broth (TSB)
was obtained from Oxoid (Thermo Fisher Scientific, Australia),
Enzymes: DNase-I was obtained from Invitrogen (Melbourne,
Australia), α-Amylase from MP Biomedicals (NSW, Australia)
and Proteinase K from Sigma-Aldrich (Sydney, Australia).
Dulbecco’s Modified Eagle Medium (DMEM) and Fetal bovine
serum (FBS) from Sigma-Aldrich (Sydney, Australia).
Determining the Change in pH of TSB
and 1 × PBS as a Function of GSH
Concentration
Glutathione powder was weighed and directly dissolved into
TSB (pH 7.18) and 1 × PBS (137 mM NaCl, 2.7 mM KCl
and 10 mM phosphate, pH 7.41) solution at room temperature
under sterile conditions (bio-safety cabinet) to give 10, 20, and
30 mM of GSH. The change in pH of TSB and 1 × PBS at
different GSH concentrations was determined using a pH meter
(Mettler-Toledo GmbH, Greifensee, Switzerland) calibrated with
pH standards of 4.0 and 7.0 and the pH values of TSB
and 1 × PBS as a function of GSH concentration reported
in Table 2.
TABLE 2 | Change in pH of TSB and PBS in presence of glutathione (GSH).
GSH concentration (mM) pH
Tryptone soy broth (TSB) 0 7.18 ± 0.08
10 6.45 ± 0.1
20 5.59 ± 0.11
30 4.77 ± 0.05
Phosphate buffer saline (PBS) 0 7.41 ± 0.03
10 5.51 ± 0.09
20 3.89 ± 0.14
30 3.21 ± 0.16
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Determining the Effect of GSH and
Antibiotics on Planktonic Growth
All clinical isolates listed in Table 1 were grown in TSB medium
for 24 h, at 37◦C and 150 rpm. After growth, the planktonic
cultures were harvested by centrifugation at 5000×g for 5 min at
10◦C, followed by removal of the supernatant and resuspension
of the bacterial pellet in TSB. The effect of GSH plus antibiotic
on planktonically-grown isolates was determined by taking
250 µL (OD600 = 0.1 ± 0.02) of bacterial cell suspension into
the wells of 96-well plates (Corning Corp. United States) and
incubating for up to 48 h, at 37◦C and 150 rpm. The bacterial
growth media contained one of: 0, 10, 20, and 30 mM GSH,
0.25–10 µg/ml ciprofloxacin or 4–16 µg/ml amikacin (only for
A. baumannii). Bacterial growth was measured at 48 h post-
treatment by recording absorbance at OD600nm using a plate
reader (Tecan infinite M1000 pro). The final increase in bacterial
growth at 48 h was measured by subtracting the absorbance at
48 h from the absorbance at 0 h. Controls were untreated, and
showing 100% growth, while tests measured percentage decrease
in bacterial growth with respect to this control.
Determining the Minimum Biofilm
Inhibitory Concentration (MBC) of
Amikacin on A. baumannii
All A. baumannii (MRAB isolates listed on Table 1) were grown
in TSB medium for 24 h, at 37◦C and 150 rpm. After growth, the
planktonic cultures were adjusted to OD600 = 0.5 ± 0.05 in TSB.
200 µl of bacterial culture was then added to the wells of 96-well
plates (Corning Corp. United States) and incubated at 37◦C for
60 min at 150 rpm. After 60 min, the wells were gently washed
once with 1 × PBS to remove any loosely adhered bacteria.
200 µL of TSB was then added, followed by further incubation
at 37◦C for 48 h and 150 rpm to initiate biofilm growth. In
amikacin-treated groups, biofilms were grown in the presence of
4–18 µg/ml amikacin dissolved in TSB. After 48 h of incubation,
the biofilms were washed once with 1× PBS, followed by addition
of 200µL of 1× PBS and 15µL of a 0.05% w/v resazurin solution.
Plates were then incubated for a further 24 h at 37◦C and 150 rpm.
Biofilm fluorescence intensity was then determined at Ex544nm
and Em590nm (Tecan infinite M1000 pro, Australia). Amikacin-
treated groups were compared for percentage decrease in biofilm
viability to 1× PBS-treated control wells showing 100% bacterial
cell viability. The percentage increase in bacterial growth at 48 h
was determined as mentioned above.
Effect of GSH and Antibiotics on
Biofilm Viability
Bacterial isolates were grown as described above. To initiate
biofilm growth, planktonic bacteria were re-suspended in TSB
and 250 µL of bacterial cell suspension (OD600 = 0.5 ± 0.05)
was added into the wells of 96-well plates (Corning Corp.
United States). Plates were incubated for 48 h, at 37◦C and
150 rpm. After 48 h, the biofilm was washed once with
1 × PBS followed by treatment (24 h, 37◦C, 150 rpm) as
follows: Control (1 × PBS), 0.5–30 µg/mL ciprofloxacin –
depending on MIC of bacterial strain, or 10 and 30 mM
GSH; or a combination of ciprofloxacin + GSH. MRAB
biofilms were treated with 4 µg/mL, 12 µg/mL, MBC (15–
16 µg/mL) and 20 µg/mL amikacin, 10 and 20 µg/mL
ciprofloxacin, 10 and 20 µg/mL Augmentin and 10 and
20 µg/mL tobramycin individually, or in combination with GSH.
All antibiotic and GSH treatment solutions were prepared in
1× PBS (pH 7.4).
After 24 h, treated biofilms were washed once with 1 × PBS
followed by addition of 200 µL of 1 × PBS and 15 µL of a 0.05%
w/v resazurin solution. Plates were then incubated for a further
24 h at 37◦C and 150 rpm. After incubation, the fluorescence
intensity of the biofilm was determined at Ex544nm and Em590nm
(Tecan infinite M1000 pro, Sydney Australia). Test biofilms were
compared for percentage decrease in biofilm viability to 1× PBS-
treated control wells showing 100% bacterial cell viability.
MRAB Biofilm Biomass Quantification by
Crystal Violet (CV) Staining
Multi-drug resistant A. baumannii biofilms were grown for 48 h
in 96-well plates as described above. After 48 h, biofilms were
washed once with 1 × PBS followed by incubation for 24 h, at
37◦C, 150 rpm with: 4, 12, and 20 µg/mL amikacin or 10, 15,
and 30 mM GSH or a combination of 30 mM GSH + 4 µg/mL
amikacin whereas, controls were treated with 1 × PBS. All
test solutions were prepared in 1 × PBS (pH 7.4). After 24 h,
treated biofilms were washed once with 1 × PBS. The biofilm
biomass attached to the wells was then stained with 200 µL 0.05%
(w/v) CV and incubated a further 1 h at 37◦C, 150 rpm. After
incubation, cells were washed three times with 1× PBS to remove
excess CV stain. The pre-stained biofilm was then allowed to
dry for 15 min at 37◦C, after which it was dissolved using 80%
v/v ethanol and transferred into new 96-well plate for biomass
quantification at OD550nm using a Tecan plate reader (Infinite
M1000 pro). Controls were treated with 1 × PBS and showed
100% growth, while tests measured the percentage decrease in
biofilm biomass with respect to this control.
Effect of Enzymatic Treatment on
MRAB Biofilm Biomass
Multi-drug resistant A. baumannii biofilms were grown for 48 h
in 96-well plates as described above. After 48 h, biofilms were
washed once with 1 × PBS followed by treatment with different
enzyme solutions prepared in 1 × PBS, pH 7.4, including: 5, 10,
20, and 40U DNase-I, 100, 200, 500 and 1000 µg/ml amylase
and 50, 100, 200 and 500 µg/ml Proteinase K, for 24 h, at 37◦C
and 150 rpm, the control was treated with 1 × PBS alone. After
24 h, treated biofilms supernatant washed once with 1 × PBS.
The biofilm biomass attached to the wells was then stained with
0.05% (w/v) CV and biofilm biomass quantified using the above
protocol. Control group normalized as 100% biofilm biomass
and enzyme-treated groups were compared with the control to
measure percentage decrease in biomass.
Analysis of MRAB Biofilm Architecture
Using Confocal Laser Scanning
Microscopy (CLSM)
To initiate biofilm growth, 500 µL MRAB-3 (OD600 = 0.5± 0.05)
in TSB was added to microscope glass slides and incubated
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at 37◦C in a static incubator for 48 h. After 48 h, biofilms
were washed once with 1 × PBS and treated using one of
the following: 30 mM GSH or 4 µg/mL amikacin individually
or a combination of 30 mM GSH + 4 µg/mL amikacin.
Enzymatic treatment included 40U DNase-I, 1000 µg/ml
Amylase, 500 µg/ml Proteinase K and a combination of 40U
DNase-I + 4 µg/mL amikacin or 40U DNase-I + 30 mM
GSH. Finally, MRAB-3 biofilms were also subjected to a three-
part combination treatment: 30 mM GSH + 40U DNase-
I + 4 µg/mL amikacin. For control, MRAB-3 biofilms were
treated with 1 × PBS. All treated biofilms were then incubated
for 24 h at 37◦C in a static incubator. After 24 h incubation,
control and all treated biofilms were washed three times with
1 × PBS to remove any planktonic/loosely bound bacterial cells.
Biofilms were then stained with a live/dead stain (Bacterial
viability kit, Life Technologies Inc., United States) for 30 min
in the dark and cells were then visualized by CLSM (Olympus
FV1200, Australia) with Ex473 and 559nm and Em500 and
637nm, for Syto-9 (green-live) and propidium iodide (red-dead)
staining, respectively. ImageJ software was used to generate
images and quantify percentage of live and dead biofilm
cells for biovolume.
Analysis of the DNA–GSH Interaction by
Circular Dichroism
A Circular Dichroism (CD) Spectropolarimeter (Jasco 815,
Easton, MD, United States) was used to investigate DNA-
GSH reactions in a 1-mm path length quartz cuvette. dsDNA
(calf thymus DNA-sodium salt Type 1 fibers, Sigma-Aldrich,
Australia) and GSH stock solutions were prepared in sterile
MilliQ water. To study the interaction, 200 ng/µl dsDNA
incubated for 24 h at 37◦C, 100 rpm, in either absence or
presence of 1 mM GSH at intrinsic pH or 1 mM GSH
at neutral pH (7.2). 300 µl aliquots pipetted into cuvettes
and scanned by CD at 200–320 nm wavelength in a static
condition at 25◦C.
Investigating Effect of GSH on dsDNA by
Fluorometry
A total of 200 ng/ µl dsDNA was incubated for 24 h at
37◦C, 100 rpm, in either presence or absence of 1 mM GSH
at intrinsic pH and in 1 mM GSH at neutral pH (7.2).
After 24 h, the dsDNA concentration was quantified using
a fluorescent dye assay (dsDNABR; Qubit, Invitrogen), and
monitored with a Qubit 3.0 Fluorometer (Invitrogen, Life
Technologies, Carlsbad, CA, United States), yielding a dsDNA
concentration in µg/mL.
Effect of pH on H2O2 Production by GSH
Quantification of H2O2 production by 10 and 30 mM GSH at its
intrinsic pH (5.4 and 3.3, respectively) and at pH 7± 0.2 (buffered
using NaOH) in 1 × PBS was analyzed using a Hydrogen
Peroxide Assay Kit – (Fluorometric-Near Infrared) (Abcam,
Australia) complemented with a fluorescence plate reader (Tecan
infinite M1000 pro). The protocol used to measure H2O2 in this
study was as published by the manufacturer (Abcam – Hydrogen
Peroxide Assay Kit).
Effect of H2O2 on MRAB Biofilm Viability
Multi-drug resistant A. baumannii biofilms were grown for 48 h
in 96-well plates as described above. After 48 h, biofilms were
washed once with 1 × PBS followed by treatment with different
concentrations of 0, 5, 10, 25, and 50 µM H2O2 (prepared by
diluting an aliquot of 30% (v/v) H2O2 in 1 × PBS) for 24 h,
at 37◦C and shaking at 150 rpm. After 24 h, treated biofilm
supernatant was washed once with 1× PBS followed by addition
of 200 µL of 1 × PBS plus 15 µL resazurin 0.05% w/v solution,
and incubated for a further 24 h, at 37◦C, 150 rpm. After 24 h,
the fluorescent intensity of the biofilm was determined at Ex544nm
and Em590nm (Tecan infinite M1000 pro). The control comprised
a 1× PBS treated biofilm showing 100% viability and percentage
decrease in biofilm viability in the treated samples was calculated
with respect to this control.
Effect of GSH and GSSG on MRAB
Biofilm Viability at Neutral pH
Multi-drug resistant A. baumannii biofilms were grown for
48 h in 96-well plates as described above. After 48 h, biofilms
were washed once with 1 × PBS followed by treatment
with 30 mM GSH (pH 7 ± 0.2) and 30 mM GSH (pH
7 ± 0.2) + 4 µg/mL amikacin and also with 30 mM GSSG and
30 mM GSSG+ 4µg/mL amikacin for 24 h, at 37◦C and 150 rpm.
After 24 h, treated biofilms were analyzed for viability using the
resazurin assay as described above.
Colony Forming Unit (CFU) Count of
MRAB
Biofilms were treated with either GSH, antibiotics, or a
combination of both, for 24 h as described above. Biofilms were
then washed once with 1 × PBS and thoroughly homogenized
by pipetting, with 200 µL of 1 × PBS. To establish a CFU
count, 100 µl of homogenized suspension from each well was
added to 900 µl of 1 × PBS (final volume 1 ml). The biofilm
suspension was then serially diluted in 1 × PBS and 100 ml
aliquots were spread on TSB plates and incubated for 24 h at
37◦C. After 24 h the colonies on the plates were counted and
numbers expressed as CFU/ml.
Human Foreskin Fibroblast (HFF-1) Cell
Culture
The HFF-1 cell line (ATCC-SCRC-1041) was cultured in DMEM,
supplemented with 12% (v/v) FBS, 100 IU/ml penicillin and
100 µg/ml streptomycin. HFF-1 cells maintained in a T-25 cell
culture flask (Corning, United States) at 37◦C in a 5% (v/v)
CO2 atmosphere and harvested at 90% confluence using 0.12%
trypsin-EDTA. Cells were collected by first quenching Trypsin 1:1
(v/v) with supplemented media and transferred to 15 ml Falcon
tubes, followed by centrifugation (5 min, 2000×g, 20◦C). The
supernatant was aspirated and the cell pellet was suspended in
supplemented DMEM media for further experiments.
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MRAB-3 Growth on Pre-confluence
HFF-1 Cells
To study the effect of MRAB-3 on pre-confluence of HFF-1
cells, HFF-1 cells were cultured and harvested as above. After
harvesting, cells were plated to a density of 6 ± 0.5 × 105
cells/mL in six-well plates (Corning) and allowed to incubate for
72 h at 37◦C in a 5% (v/v) CO2 atmosphere to a confluence of
90%. 100 µL of MRAB -3 (OD600nm = 0.1 ± 0.02) suspended
in 1 × PBS was then introduced into the confluent HFF-
1-containing media and the plates allowed to incubate for a
further 24 h. Where indicated, HFF-1-containing media were
also incubated with a different treatment of either 10 or 30 mM
GSH, or 4 µg/mL amikacin alone, or a combination of 10 mM
GSH + 4 µg/mL amikacin, either in the presence or absence
of bacteria. After 24 h, the HFF-1 cells in the well plates were
imaged using phase contrast microscopy (Zeiss, Axio, Germany)
for growth appearance, adherence and confluence.
Effect of GSH on MRAB-3 Adhesion and
Biofilm Formation
MRAB-3 was cultured and harvested as above and after
harvesting at a bacterial density (OD600nm = 0.1 ± 0.02) was re-
suspended in TSB and added to six-well plates (Corning Corp.
United States) for incubation (24 h, at 37◦C and 150 rpm) to
initiate bacterial adhesion and biofilm growth. Where indicated,
biofilm growth was also initiated in both presence and absence
of 5, 10, and 30 mM GSH. After 24 h, the biofilm was washed
once with 1 × PBS and imaged using phase contrast microscopy
(Zeiss, Axio, Germany), for bacterial adhesion and colonization.
Bacterial cells adherent to the surface of six-well plates were
enumerated using ImageJ, where number of maxima present
were quantified as explained on the ImageJ process menu, on
its website3. The maxima were enumerated as this provided a
more accurate presentation of individual cells clumped together,
in comparison to simple thresholding.
Statistical Method
All statistical analysis in the manuscript were done using
Graphpad prism Unpaired t-test. The results are considered
statistically significant if “P < 0.05”.
RESULTS
GSH Changes the pH of TSB and
1 × PBS
Table 2 shows that addition of GSH materially decreased the
pH of both TSB and 1 × PBS solution. The initial pH of both
TSB and 1 × PBS was neutral (pH 7.18 and 7.41, respectively).
After addition of 10, 20, or 30 mM GSH, the pH of TSB declined
gradually to 6.45, 5.59, and 4.77, respectively. In the case of
1× PBS, the pH dropped much further, to 5.51 at (10 mM GSH),
3.89 (20 mM GSH) and to pH 3.21 (30 mM GSH).
3https://imagej.net/docs/guide/146-29.html#Flo:Maxima-outputs and https://
imagej.net/docs/menus/process.html#find-maxima
Effect of GSH on Planktonic Growth of
Clinical Bacterial Isolates
Figure 1 shows the effect of GSH (intrinsic pH) on growth of
clinical isolates over 48 h. Bacterial growth in absence of GSH
(control) is always considered as 100% growth and treatment
growth levels are compared with respect to control. At 30 mM
GSH, most bacterial species showed growth ≤50% after 48 h.
Gram-positive species: MRSA and MSSA recorded growth of
22–27% and 13–50%, respectively, whereas S. pyogenes growth
was almost completely inhibited (0–4%) at 30 mM GSH. Gram-
negative species: For A. baumannii isolates, growth varied
between 41 and 54%, Enterobacter sp. (77–91%), E. coli (4–8%)
and K. pneumoniae (52–100%). At lower concentrations (10 and
20 mM GSH), only MRSA, S. pyogenes and E. coli showed growth
≤50%. These decreases in bacterial growth specifically at 30 mM
GSH were statistically significant (P < 0.05) when compared to
the control and 10 mM GSH-treated condition.
MBC of A. baumannii Isolates in
Presence of Amikacin
Table 3 and Supplementary Figure S2 show the MBC of
the MRAB isolates. For MRAB-1 (Urine), MRAB-3 (skin) and
MRAB-3 (catheter) the MBC was 16 µg/ml, whereas, for the
MRAB-2 (catheter) isolate the MBC was 15 µg/ml (Table 3).
In comparison to the control, MRAB isolates showed significant
(P < 0.05) decreases in biofilm viability at all concentrations
of amikacin, except for MRAB-4 (catheter isolate), which
showed a significant decrease starting at 10 µg/ml amikacin
(Supplementary Figure S2).
Effect of GSH and Antibiotics on
Bacterial Biofilm Viability
Figure 2 shows the effect of antibiotics and GSH on 48 h
biofilms. Amongst Gram-positive bacteria, ciprofloxacin (MIC
concentration 10 and 4 µg/ml for S. aureus MRSA and MSSA,
and S. pyogenes, respectively) showed significant decreases in
biofilm viability (∼40–61% and 37–50% for MRSA/MSSA and
18–54% for S. pyogenes, respectively) in comparison to untreated
controls. An increase in ciprofloxacin concentration: to 30 µg/ml
(S. aureus) and 12 µg/ml (S. pyogenes) showed further decreases
in biofilm viability for few isolates: an average of 25% for strains
MRSA-1 MRSA-2 and MSSA-3, and 6% for S. pyogenes (SP-1).
Treatment with GSH at biological concentration (10 mM) did not
show any significant decrease in biofilm viability in any isolates
of MRSA and MSSA. However, S. pyogenes (SP-1) (56%) and SP-
2 (68%) were more sensitive to GSH and showed a significant
decrease in biofilm viability (P < 0.05). At a GSH, concentration
of 30 mM an increase in biofilm disruption amongst all Gram-
positive isolates was observed. For MRSA and MSSA, biofilm
viability at 30 mM GSH ranged between 1–33% and 1–20%,
respectively, and for S. pyogenes isolates, between 4 and 22%.
Combination treatment comprising 30 mM GSH and 10 µg/ml
ciprofloxacin showed further significant (P < 0.05) decreases
in biofilm viability in all MRSA strains (0–22%). For MSSA
(1–10%), there was a significant decrease only for strains MSSA-2
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FIGURE 1 | Effect of Glutathione (GSH) on growth of bacterial species isolated from Sydney hospitals. GSH showed concentration-dependent effects in inhibiting
bacterial growth. 10 mM GSH did not affect bacterial growth for most of the isolates whereas; 20 mM GSH showed around 50% decrease in bacterial growth for all
isolates of Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive S. aureus (MSSA) and a less then 25% decrease for one S. pyogenes and
E. coli. 30 mM GSH is very effective inhibiting greater than 50% growth with almost complete inhibition in case of S. pyogenes and E. coli and resistance in case of
Enterobacter species and K. pneumoniae. Data represent mean ± SD; n = 4 experiments performed in biological replicates. Dotted line (- - -) in each graph indicates
50% bacterial growth. ∗P < 0.05 (statistically significant) when compared to control, #P < 0.05 (statistically significant) when compared to 10 mM GSH.
and MSSA-3, and significant decreases in for all S. pyogenes
strains (0–12%).
Amongst the Gram-negative bacterial isolates, Enterobacter
sp., and E. coli were found to have the lowest ciprofloxacin
MIC (0.5 µg/ml) while for K. pneumoniae, the ciprofloxacin
MIC was 10 µg/ml. At their respective MIC, biofilm viability
of all isolates of Enterobacter sp. (15–64%), E. coli (30–58%),
and K. pneumoniae (29–55%) showed significant decrease in
viability compared to the control. However, further increases
in ciprofloxacin concentration (to 2 µg/ml) did not result in
TABLE 3 | Minimum biofilm inhibitory concentration (MBC) of multidrug resistant
isolates of Acinetobacter baumannii (MRAB) in the presence of Amikacin.
Acinetobacter baumannii Amikacin (µg/ml)
MRAB-1 Urine 16
MRAB-2 Catheter 15
MRAB-3 Skin 16
MRAB-4 Catheter 16
significant decreases in viability for Enterobacter sp., and E. coli.
On the other hand, all K. pneumoniae strains showed a large
decrease in biofilm viability (21–25%) at 30 µg/ml ciprofloxacin,
with statistical significance (P < 0.05) for K. pneumoniae
(KP-3) neck wound isolate. In the case of amikacin sensitive
A. baumannii isolates, treatment at the MIC (4 µg/ml) of
amikacin showed a significant (P < 0.05) decrease in biofilm
viability (36–67%). A further significant (P < 0.05) decrease in
biofilm viability (8–42%) observed when amikacin concentration
increased to 20 µg/ml.
A biological GSH concentration (10 mM) did not show
any significant decrease in biofilm viability in most of the
Gram-negative isolates. This is in contrast to use of the
highest GSH concentration (30 mM), which showed a drastic
(significant, P < 0.05) decrease in biofilm viability for all clinical
isolates including A. baumannii (16–38%), Enterobacter sp.
(0–20%), E. coli (1–12%) and K. pneumoniae (9–17%). Combined
treatment with 30 mM GSH the + MIC concentration of
antibiotics showed significant decreases (P < 0.05) in biofilm
viability for most of the isolates: A. baumannii (4–10%),
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FIGURE 2 | GSH reduces biofilm viability and enhances antibiotic efficiency. GSH showed a concentration-dependent effect in reducing biofilm viability. Ciprofloxacin
(1–3 × MIC) significantly reduced biofilm viability of MRSA, MSSA, S. pyogenes, Enterobacter sp., E. coli and K. pneumoniae. For A. baumannii amikacin
(1–5 × MIC) significantly reduced biofilm viability when compared to control. 10 mM GSH did not have any effect on biofilm viability, but 30 mM GSH significantly
reduced biofilm viability of all bacterial species. A combination of 30 mM GSH and antibiotic of choice further reduced biofilm viability. ∗P < 0.05 when compared to
control, #P < 0.05 when compared to antibiotic at 1 × MIC and •P < 0.05 when compared to 30 mM GSH. Data represent the mean ± SD of n = 4 experiments
performed in biological replicate.
Enterobacter sp. (0–9%), E. coli (1–6%) and K. pneumoniae
(2–10%) when compared to treatment with MIC concentration
antibiotic or 30 mM GSH alone.
Effect of GSH and Amikacin on MRAB
Biofilm Biomass
Crystal violet assays measured biofilm biomass of MRAB isolates
and showed a statistically significant decrease in biomass when
treated with 4–20 µg/ml amikacin or 30 mM GSH alone or in
combination, compared to untreated biofilm (Figure 3A). With
MIC concentration (4 µg/ml) amikacin recorded 57–67% biofilm
biomass whereas, at the highest concentration of amikacin
used in this study (20 µg/ml) recorded only 38–46% biomass.
When treated with 30 mM GSH, the biomass percentage ranged
between 43 and 52%, however, when compared to 4 µg/ml
amikacin, only MRAB-1 and MRAB-2 showed a significant
decrease (P < 0.05). Interestingly, a combination of 30 mM
GSH + 4 µg/ml amikacin showed statistically significant
decreases in biomass (40–45%) for all isolates in comparison to
4 µg/ml amikacin alone.
Enzymatic Treatment on MRAB Biofilm
We also investigated the effect of DNase-I, amylase and
Proteinase K on all MRAB biofilm biomass using CV assays
(Figure 3B). In comparison to the control, DNase-I-treated
MRAB biofilms for all strains at 20 and 40U showed a statistically
significant reduction in biofilm biomass (biomass recorded as
56–73%) whereas, at low concentration (5U) only MRAB-2
and at 10U DNase I only MRAB-1, 2, and 3 showed a
significant reduction in biomass. When treated with 500 and
1000 µg/ml amylase, the biomass ranged between 61 and 79%,
with significant reductions for MRAB-1, MRAB-2, and MRAB-3.
With 200 µg/ml amylase, only MRAB-1 and MRAB-4 showed a
significant reduction whereas, 100 µg/ml amylase did not result
in biomass reduction. Treatment with 100, 200, and 500 µg/ml
Proteinase K resulted in a biomass between 54 and 93% of
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FIGURE 3 | Effect of GSH, antibiotics and enzymes on MRAB biofilm biomass and biofilm architecture. (A) Biofilm biomass of MRAB isolates measured using the
crystal violet assay showed statistically significant decreases in biomass when treated with amikacin, GSH alone or in combination, compared to untreated control.
Amikacin at 1 × MIC reduced biomass to 58–67% whereas at 5 × MIC, biomass was reduced to between 38 and 46% for all isolates. 30 mM GSH decreased
biomass to 43–52%, while a combination of GSH + amikacin decreased biomass by 40–45% for all isolates. (B) Both 20 and 40U DNase-I significantly reduced
biofilm biomass (56–73% for all MRAB isolates). At higher concentrations of amylase (500 and 1000 µg/ml) and Proteinase K (200 and 500 µg/ml) treatment
reduced biofilm biomass by 61–79% and 54–93%, respectively. (C) Biofilm architecture of MRAB-3 imaged using CLSM and complemented with Live/dead bacterial
viability stain, showed a marked and distinct type of disruption in biofilm architecture when treated singly with amikacin, GSH, or enzyme, or combinations thereof. In
panels (A,B) ∗P < 0.05 when compared to control and #P < 0.05 when compared to 4 µg/ml amikacin. Data represent the mean ± SD of n = 4 experiments
performed in biological replicate.
control, and a significant difference was observed only for the
urine and skin isolates MRAB-1 and -3.
Amikacin, GSH and Enzymes Modulate
MRAB-3 Biofilm Architecture
The biofilm architecture of MRAB-3 changed significantly when
subjected to different treatments Figure 3C. The effect of 4 µg/ml
amikacin, 30 mM GSH, 40U DNase-I, 1000 µg/ml amylase and
500 µg/mL Proteinase K, individually or in combination (two or
three components) on established biofilms of MRAB-3 is shown
in Figure 3C. CLSM complemented Live/dead biofilm imaging
and showed marked disruption in the biofilm architecture
of MRAB when treated for 24 h with GSH or enzymes.
The DNase-I treated biofilm showed considerably different
biofilm architecture when exposed to other enzymes (amylase
and Proteinase K). However, treatment with amikacin alone
did not disrupt the biofilm, but enhanced more dead (red)
biofilm cells than in the corresponding control. Conversely,
for combinations of GSH + amikacin, DNase-I + amikacin,
GSH + DNase-I and GSH + DNase-I + amikacin, a larger
increase in biofilm disruption and more modulated changes
in biofilm architecture were visible than in the corresponding
individual treatment regimens and control. A comparison of the
percentage of live/dead cells in biofilm showed an increase in
live percentage for the control (∼85%), whereas, treated biofilms
showed a decrease in live biofilm of between 39 and 73%.
A statistically significant difference was observed for amikacin,
GSH, the combination of GSH+ amikacin, Proteinase K, DNase
I + amikacin, GSH + DNase I and GSH + DNase I + amikacin
(Supplementary Figure S3).
Modulation and Cleavage of dsDNA Due
to GSH Acidity
Circular Dichroism peaks clearly indicated that GSH at its
intrinsic pH drastically modulates the DNA sugar phosphate
backbone (peak 247 nm) whereas GSH at neutral pH did not alter
this peak (Figure 4A). GSH by itself does not have a peak at or
near 247 nm, but rather peaks at around 220 nm (Figure 4B).
Qubit fluorometer quantification of dsDNA showed that GSH
at intrinsic pH reduced dsDNA concentration to 5 µg/ml in
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FIGURE 4 | Effect of GSH on dsDNA. The circular dichroism curve showed dsDNA modulation at its sugar phosphate backbone. (A) dsDNA has a peak at 247 nm
at intrinsic pH, and no change occurs when it is exposed to GSH at pH 7.2. (B) Intrinsic and buffered GSH curve showed a peak at around 220 nm. (C) Qubit
fluorometer quantification of dsDNA showed significant reduction in dsDNA concentration when exposed to GSH at intrinsic pH. ∗P < 0.05 when compared to
control and GSH at neutral pH.
comparison to 176 µg/ml (GSH at neutral pH) and 184 µg/ml
for control/untreated (Figure 4C).
Effect of GSH at Neutral pH on MRAB
Biofilm Viability
Figure 5A shows the effect of 30 mM GSH (buffered to pH 7),
alone and in combination with 4 µg/ml amikacin on MRAB
biofilm viability. At neutral pH, GSH showed only small decreases
in MRAB biofilm viability (76–94%) with statistically significant
decreases only for MRAB-1 and MRAB-3 in comparison
to control. When combined with amikacin, biofilm viability
decreased (47–55%) significantly (P < 0.05) when compare to
both control and 30 mM GSH (pH 7) alone treatment.
Effect of GSSG on MRAB Biofilm Viability
MRAB biofilms subjected to treatment with 30 mM GSSG
at intrinsic pH showed statistically significant decreases in
biofilm viability (11–14%) when compared to control biofilms.
Further significant decreases of 5–6% in MRAB biofilm viability
compared to GSSG alone treatment were observed when biofilms
were exposed to 30 mM GSSG+ 4 µg/ml amikacin (Figure 5B).
The Influence of pH on H2O2 Production
by GSH
Figure 5C showed that fluorescent intensity corresponds to
standard H2O2 concentration, as measured using a H2O2
assay kit. Standard H2O2 data were used to determine H2O2
production by GSH at intrinsic pH i.e., 10 mM = pH 5.51 and
30 mM = pH 3.2, and at buffered neutral pH 7. In general, at
intrinsic pH GSH produced a significantly higher concentration
H2O2 (higher fluorescent intensity) than at its corresponding
neutral pH (P < 0.05). 30 mM GSH (intrinsic pH) showed
3 and 4 fold increases in H2O2 production in comparison
to 30 mM GSH (pH 7) and 10 mM GSH (at intrinsic pH),
respectively, (Figure 5D).
H2O2 Impact on MRAB Biofilm Viability
Multi-drug resistant A. baumannii biofilms, when subjected to
H2O2 treatment, showed variations in biofilm viability among
isolates. MRAB-1 and MRAB-3 (urine and skin isolates) showed
a statistically significant decrease in biofilm viability, to 53 and
58%, respectively, at 50 µM H2O2 (P < 0.05). However, for the
catheter isolates (MRAB-2 and MRAB-4), biofilm viability was
similar to control at all H2O2 concentrations (Figure 5E).
Post-treatment CFU Counts of MRAB
Biofilms
Control/untreated biofilms and DNase-I-treated biofilms had
a CFU/ml at log10 of 9-10.2. The CFU/ml of amikacin
(4–80 µg/ml) and GSH (30 mM)-treated biofilms were log10
5.1-8.2 and 5.1-6.5, respectively. Double combination treatments
comprising: DNase-I (40U) + amikacin (4 µg/ml), GSH
(30 mM)+ amikacin (4–80 µg/ml) and GSH (30 mM)+DNase-
I (40U) resulted in decreased CFUs/ml of log10 4.9–6.2, 3.7–5.3
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FIGURE 5 | Effect of GSH, GSSG and H2O2 at neutral pH on MRAB biofilm viability. (A) 30 mM GSH (buffered to pH 7) resulted in a small biofilm viability decrease
(76–94% viable), while combination with amikacin enhanced the decrease significantly (47–55% viable) when compared to both control and 30 mM GSH (pH 7)
alone. (B) 30 mM GSSG alone and in combination with 4 µg/ml amikacin significantly decreased MRAB biofilm viability to 11–14% and 5–6%, respectively, when
compared to control. (C,D) Standard H2O2 data used to determine H2O2 production by 10 and 30 mM GSH in 1 × PBS at intrinsic pH, and at buffered neutral pH
7. At intrinsic pH, GSH produced significantly more H2O2 (higher fluorescent intensity) than at its corresponding neutral pH concentration. (E) H2O2 treatment
showed variation in MRAB biofilm viability among isolates. When compared to control only, MRAB-1 and MRAB-3 isolates showed statistically significant decreases
in biofilm viability at all H2O2 concentrations. However, for MRAB-2 and MRAB-4, biofilm viability was similar to control at all H2O2 concentrations. ∗P < 0.05
compared to control •P < 0.05 when compared to 30 mM GSH (A) and 30 mM GSSG (B) and #P < 0.05 when compared to all other conditions (D). Data
represent the mean ± SD of n = 4 experiments performed in biological replicate.
FIGURE 6 | CFU count of MRAB biofilms after GSH, amikacin and DNase-I treatment: CFU/ml of control, amikacin, DNase-I and GSH of MRAB isolates was log10
9–10.2, log10 5.1–8.2, log10 8.3–10.2 and 5.1–6.5, respectively. Combination treatments comprising: DNase-I + amikacin, GSH + amikacin and GSH + DNase-I on
biofilms resulted in a CFU/ml of log10 4.9–6.2, 3.7–5.3, and 4.6–5.9, respectively. The triple combination of GSH + DNase-I + amikacin decreased the CFU/ml to
log10 4.3–4.9. Data represent the mean ± SD of n = 3 experiments performed in biological replicate. ∗P < 0.05 compared to control, #P < 0.05 when compared to
amikacin vs. GSH + amikacin and ∗∗P < 0.05 when compared to GSH vs. GSH + amikacin.
and 4.6–5.9, respectively. GSH (30 mM) + amikacin (MBC)
showed the most effective decrease in CFU/ml (1og10 3.7-4.1).
Whereas, triple combination treatment (30 mM GSH + 40U
DNase-I + 4 µg/ml amikacin) resulted in a CFU/ml between
log10 4.3–4.9. For all treatment conditions (except for DNase
I alone treatment) the decreases in CFU/ml were statistically
significant when compared to 1× PBS treated control (P< 0.05).
In addition, when treatment with amikacin alone was compared
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FIGURE 7 | Effect of GSH on MRAB colonization and HFF-1 confluence. (A) Pre-confluent HFF-1 cells were completely disrupted when exposed to MRAB-3,
whereas GSH, amikacin alone or in combination, inhibited MRAB colonization and retained HFF-1 cell confluence. (B,C) GSH alone was shown to significantly
decrease MRAB-3 adhesion and colonization. ∗P < 0.05 compared to control and data represent the mean ± SD of n = 3 experiments performed in biological
replicate.
with GSH + amikacin, the reduction in CFU/ml in combination
treatment was significant, (P < 0.05) especially at higher
amikacin concentrations (Figure 6).
GSH Fosters HFF-1 Confluence and
Inhibits MRAB Colonization
Figure 7A shows that MRAB infected and completely removed
pre-confluence HFF-1 cells. Treatment with GSH or amikacin
alone drastically reduced MRAB adhesion and colonization and
concurrently induced a greater than 50% HFF-1 increase in
adhered cells compared to MRAB-alone infected HFF-1. The
combination of GSH + amikacin showed complete inhibition of
MRAB colonization and maintenance of HFF-1 cell confluence
similar to the control. GSH alone in a concentration dependent
manner hindered MRAB-3 adhesion and colonization on
surfaces, with 30 mM GSH showing the greatest reduction
in bacterial adhesion (Figure 7B). Quantification of MRAB-3
adhesion on surfaces showed approximately 2.7 × 104 bacteria
per 0.25 × 0.325 mm2 (area) for the 1 × PBS treated control
whereas, in the presence of GSH bacterial adhesion decreased
significantly (>5 × 103 bacteria) especially at 10 and 30 mM
GSH (Figure 7C).
DISCUSSION
Glutathione in naturally present in mammalian cells. However,
its biological concentration varies considerably. Intracellular
fluid (cytosol) has up to 10 mM of GSH whereas the plasma
GSH concentration is very low (micromolar range) (Forman
et al., 2009). In cystic fibrosis, the efficiency of intrinsic GSH
synthesis is very low compared to healthy populations and
studies have demonstrated that GSH deficiency leads to recurrent
bacterial infections (Roum et al., 1993; Ristoff et al., 2001;
Ghezzi, 2011). An interesting feature of GSH revealed in this
study is the intrinsic acidity of GSH, and how this inhibits
bacterial growth and disruption of biofilms (Figures 1, 2).
At biological levels (10 mM), GSH had no disruptive impact
on the bacterial species tested with the exception of for
S. pyogenes, whereas at 30 mM GSH, a greater than 50%
decrease in bacterial growth for most bacterial species was
observed, with S. pyogenes growth nearly completely inhibited.
Our findings were corroborated by a previous study (Schairer
et al., 2013), which also reported that concentration-dependent
GSH mediated acidity (pH < 4) inhibits bacterial growth.
Interestingly, the Gram-negative species K. pneumoniae and
Enterobacter sp. used in this study were highly resistant to 30 mM
GSH (Figure 1). This could potentially be due to bacterial ability
to confront low pH/acid via mechanisms such as removal of H+
via a proton pump, production of enzymes and proteins to repair
degraded proteins and DNA, modulation in cell envelope, and
changes in cell density (Cotter and Hill, 2003).
30 mM GSH showed excellent levels of disruption and
killing, with a greater than 50% reduction in biofilm viability
for all bacterial species used in this study (P > 0.05, for all
isolates). Reduction in biofilm viability achieved by treatment
with 30 mM GSH alone is either analogous to or improved in
comparison to maximum antibiotic concentrations (3, 4, and
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5 × MIC) used in this study. Most remarkably, for almost all
bacterial isolates, 30 mM GSH was shown to enhance antibiotic
efficiency, indicating the practicality of GSH in treatment of
biofilm-associated infections (Figure 2). Our study showed that
the MBC of amikacin for the MRAB isolates tested was about
four fold higher compared to its MIC (4 µg/ml) (Table 3 and
Supplementary Figure S2). MRAB biofilm treated with 30 mM
GSH alone and GSH + amikacin (1 × MIC) demonstrated
enhanced reduction in biomass compared to 1 ×MIC amikacin
alone (Figure 3A). In general, in all treated conditions a drastic
modulation of the MRAB biofilm architecture was evident, with
enhanced disruption and an increase in dead (red) biofilm cells
(Figure 3C and Supplementary Figure S3).
Biofilm disruption by GSH acidity is triggered through
cleaving and destabilization of biopolymers such as extracellular
DNA (eDNA), polysaccharides and proteins. By using CD and
Qubit fluorometry, we confirmed that acidic GSH cleaves dsDNA
and destabilizes its double helix structure (Figure 4). A significant
change in pH affects the structure of all macromolecules, for
instance, presence of a higher proportion of H+ or low pH
solution cleaves DNA double helix strands by protonating the
DNA phosphodiester groups and consequently destabilizing the
hydrogen bonds linking DNA nitrogenous bases guanine and
cytosine (G-C) (Sorokin et al., 1986). Similarly, low pH triggers
acid-induced protein unfolding and degradation via hydrolysis
and aggregation (Estey et al., 2006). Bacterial cells exposed
to acidic pH undergo substantial structural damage to their
cell wall, and intracellular macromolecules such as DNA and
proteins (Cotter and Hill, 2003). Rao et al. (1984) showed
that at low pH (4–6), bacteria undergo significant modulation
in their cytological characteristics, physiological activity and
decline in population. In contrast, Dwyera et al. (2014) claim
that pre-treatment of bacteria (E. coli) with antioxidants (GSH
and Ascorbic acid), reduces antibiotic-mediated reactive oxygen
species production and consequently limits antibiotic lethality.
The role of biopolymers in MRAB biofilm integration was
also revealed by the enzymatic part of the treatments, which
resulted in a significant reduction in biofilm biomass and
distinctive disruption in biofilm architecture. DNase-I and
amylase treatment confirmed, through total loss of structure,
that eDNA and polysaccharides are the common biopolymers
responsible for MRAB biofilm matrix integration. Interestingly,
MRAB urine and skin isolates must contain significant levels
of protein integrated within their biofilms, as evidenced by
Proteinase K treatment (Figure 3B). This assumption was
confirmed through CLSM images of MRAB-3 (skin isolate)
and provided further evidence of the distinct modulation of its
biofilm architecture after being subjected to different enzyme
solutions. DNase-I treatment showed more single colonies
uniformly distributed on the surface, whereas CLSM images
revealed amylase and Proteinase treatment showed a mixture of
small and big clusters in biofilm architecture (Figure 3C). The
combination of DNase-I+ amikacin resulted in a strong increase
in dead biofilm compared to DNase I treatment alone, and
the triple therapy combination of GSH + DNase-I + amikacin
showed the highest level of biofilm disruption (Figure 3C).
Results from this study confirm that MRAB biofilm matrix
integration is significantly dependent on the biopolymers present,
and this finding aligns with previous studies, which reported
that eDNA, polysaccharides and proteins play an essential role
in A. baumannii biofilm formation and stability (Choi et al.,
2009; Kari et al., 2011; Sahu et al., 2012; Gawande et al., 2014).
By allowing the biopolymers to directly bind to antibiotics and
inhibiting antibiotic penetration into the biofilm, the matrix acts
as a shield for the bacteria concealed inside it (Lewis, 2001; Wilton
et al., 2016; Clayton and Thien-Fah, 2017).
The efficacy of GSH is enhanced by its intrinsic acidity (pH
3.21 in 1 × PBS and 4.77 in TSB) at 30 mM GSH. Buffering
of 30 mM GSH (in TSB and 1 × PBS), with pH to neutral
(7) had no impact on bacterial growth (data not shown) and
very minimal impact on biofilm viability (Figure 5A). On the
other hand, addition of 30 mM GSSG, an oxidized form of GSH
which has no antioxidant properties but is intrinsically acidic,
resulted in a reduction in biofilm viability comparable to or
greater than 30 mM GSH at intrinsic pH levels (Figure 5B). This
result indicates that GSH concentration is likely dependent on
acidity and that its acidity plays a significant role in its biofilm
disruption activity. Previous studies also reported that butyric
acid (pH> 5) has a significantly inhibits bacterial growth and this
could be possibly due to acidification of the bacterial cytoplasm
and protonation-(H+)-triggered modulation of bacterial cell ATP
synthesis (Sun et al., 1998).
The thiol group of GSH may be a significant factor
in the biofilm disruption process. Studies of another thiol-
containing antioxidant N-acetylcysteine (NAC), at its intrinsic
pH, showed that it destabilizes the biofilm matrix by chelating
divalent cations (e.g., Ca2+ and Mg2+), inhibition of bacterial
extracellular polysaccharide production, modulation of bacterial
cell physiology and the impact on its metabolism (Olofsson et al.,
2003; Zhao and Liu, 2010; Blasi et al., 2016; Choid et al., 2018).
Whether the thiol group plays a greater role in biofilm disruption
than the acidity of GSH has yet to be determined. Nevertheless,
results from our study clearly suggest that GSH-mediated biofilm
disruption is negligible at neutral pH, and thus the acidity of GSH
is a critical factor in the effectiveness of its biofilm disruption and
reduction of bacterial viability.
Our investigation of H2O2 production by GSH during
disruption and killing of MRAB biofilms produced interesting
results (Figures 5C–E). Previous studies had reported that GSH
undergoes auto-oxidation to produce H2O2 (Albro et al., 1986).
In this study, we showed that H2O2 production is higher in
acidic conditions, mainly due to the presence of more H+ ions
(Figure 5D). GSH-mediated H2O2 production is likely to have
had an impact on the biofilms from two of the four MRAB
isolates. MRAB urine and skin isolates showed significant biofilm
viability reductions of up to 40%, whereas catheter isolates did
not display significant viability reductions (Figure 5E). MRAB
are catalase positive and so it is not surprising to see a minimal
effect of H2O2 on viability of their biofilms. Another interesting
outcome was that GSH treatment did not change the efficiency
of MRAB resistance to the antibiotics (Augmentin, ciprofloxacin,
gentamicin and tobramycin) tested in this study (Supplementary
Figures S1A–D), indicating that GSH does not influence MRAB’s
gene expression profile, however, further research is needed
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to ascertain the validity of these findings. In parallel with
the above observations, the use of GSH in a combination
treatment of MRAB especially with an antibiotic (at highest
concentration, 5 × MBC) resulted in the lowest recoverable
CFU count (i.e., the lowest level of viability) (Figure 6). An
additional advantage of GSH is that it helps in maintaining
and fostering HFF-1 cell confluence while significantly inhibiting
MRAB adhesion, colonization and HFF-1 infection (Figure 7).
However, it should be noted that GSH at high concentrations
(e.g., 30 mM) induces morphological changes in HFF-1 cells
(Supplementary Figure S1E).
The thiol-based antioxidant NAC has undergone clinical trials
for use in respiratory related infections (Schito et al., 2007;
Macchi et al., 2012). However, in some cases GSH has an added
advantage in comparison to NAC alone, because in groups such
as the immunocompromised, those with cystic fibrosis and liver
dysfunction, as well as the elderly, the capacity to synthesis GSH
has already significantly diminished. This could potentially lead
to an inability to convert cysteine or NAC into GSH (Schmitt
et al., 2015). A study also showed that a novel sublingual form
of GSH (Sublinthions by Laboratoires Le Stum, Larmor-Plage,
France) enhances the bioavailability of GSH in plasma when
compared to oral NAC supplementation (Schmitt et al., 2015).
In this study, we demonstrated that GSH acidity plays a key
role in biofilm disruption of many MDR bacterial isolates and
enhances antibiotic efficacy. With MRAB, biofilm integration
is primarily dependent on eDNA and polysaccharides and the
cleaving of these biopolymers enhances the antibiotic’s efficiency
in killing the bacteria.
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FIGURE S1 | Effect of different antibiotics on MRAB biofilm viability. MRAB
biofilms subjected to Augmentin (A), ciprofloxacin (B), gentamicin (C) and
Tobramycin (D) showed decreases in biofilm viability of 56–94%, 58–72%,
60–100% and 70–90%, respectively. (A–D) When antibiotics were combined with
30 mM GSH, MRAB biofilm viability decreased significantly to 14–27%.
(E) Modulation in HFF-1 cell morphology observed when exposed to GSH 30 mM.
For Panels (A–D), ∗P < 0.05 compared to control, #P < 0.05 compared to the
respective antibiotic concentrations. Data represent the mean ± SD of n = 4
experiments performed in biological replicate.
FIGURE S2 | The MBC of amikacin on MRAB isolates. All MRAB isolates except
MRAB-4 showed a significant decrease in their biofilm viability at the lowest
amikacin concentration (4 µg/ml). MRAB-4 showed a significant reduction from
10 µg/ml amikacin (A). In comparison to the control, growth of MRAB isolates in
presence of amikacin were significantly reduced from 6 µg/ml amikacin for
MRAB-1 and -2, and from 8 and 10 µg/ml amikacin for MRAB-3 and -4,
respectively (B). The MBC of all MRAB isolates are similar 15–16 µg/ml.
∗P < 0.05 compared to control, #P < 0.05 compared to 4 µg/ml amikacin and
data represent the mean ± SD of n = 4 (A) and n = 3 (B) experiments performed
in biological replicate.
FIGURE S3 | Quantification of live/dead biofilm biomass of MRAB-3. The control
showed the highest percentage of live biofilm (∼85%) in comparison to their
treatment conditions. Treatment with amikacin and GSH alone showed
approximately 54 and 56% live biofilm, while enzymatic treatment resulted in
between 54 and 73% live biofilm. Triple combination treatment resulted in the least
percentage of live biofilm (∼39%). ∗P < 0.05 compared to control. Data represent
the mean ± SD of n = 3 experiments performed in biological replicate.
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